Chemopotentiation by PARP inhibitors in cancer therapy

Pharmacological Research

Volumn 52, Issue 1 SPEC. ISS., 2005, Pages 25-33

  Tentori, Lucio ^a   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Base excision repair; Camptothecin; Cancer; Me Lex; Poly(ADP ribose) polymerase; Temozolomide

Indexed keywords

3 AMINOBENZAMIDE; 4 AMINO 1,8 NAPHTHALIMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ACRIDONE DERIVATIVE; AG 14361; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARMUSTINE; CEP 6800; CISPLATIN; DACARBAZINE; ETOPOSIDE; GL 331; GPI 15427; GYRASE INHIBITOR; IRINOTECAN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; O (2 HYDROXY 3 PIPERIDINOPROPYL)NICOTINIC AMIDOXIME; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER; CANCER THERAPY; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME ACTIVATION; EXCISION REPAIR; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RNA TRANSCRIPTION;

EID: 19444375973     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2005.02.010     Document Type: Article

References (56)

1. J.C. Ame, C. Spenlehauer, and G. de Murcia The PARP superfamily Bioessays 26 2004 882 893
2. M.S. Satoh, G.G. Poirier, and T. Lindahl NAD(+)-dependent repair of damaged DNA by human cell extracts J Biol Chem 268 1993 5480 5487
3. V. Schreiber, J.C. Ame, P. Dolle, I. Schultz, B. Rinaldi, and V. Fraulob Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1 J Biol Chem 277 2002 23028 23036
4. H.C. Ha, and S.H. Snyder Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion Proc Natl Acad Sci USA 96 1999 13978 13982
5. S.W. Yu, H. Wang, M.F. Poitras, C. Coombs, W.J. Bowers, and H.J. Federoff Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor Science 297 2002 259 263
6. L. Tentori, I. Portarena, and G. Graziani Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors Pharmacol Res 45 2002 73 85
7. E.S. Newlands, M.F. Stevens, S.R. Wedge, R.T. Wheelhouse, and C. Brock Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 1997 35 61
8. G. Fronza, and B. Gold The biological effects of N3-methyladenine J Cell Biochem 91 2004 250 257
9. F. Dantzer, V. Shereiber, C. Niedergang, C. Trucco, E. Flatter, and G. De La Rubia Involvement of poly(ADP-ribose) polymerase in base excision repair Biochimie 81 1999 69 75
10. S.L. Gerson MGMT: its role in cancer aetiology and cancer therapeutics Nat Rev Cancer 4 2004 296 307
11. S. D'Atri, L. Tentori, P.M. Lacal, G. Graziani, E. Pagani, and E. Benincasa Involvement of the mismatch repair system in temozolomide-induced apoptosis Mol Pharmacol 54 1998 334 341
12. L. Levati, G. Marra, T. Lettieri, S. D'Atri, P. Vernole, and L. Tentori Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents Genes Chromosomes Cancer 23 1998 159 166
13. P. Karran, J. Offman, and M. Bignami Human mismatch repair, drug-induced DNA damage, and secondary cancer Biochimie 85 2003 1149 1160
14. L. Stojic, R. Brun, and J. Jiricny Mismatch repair and DNA damage signalling DNA Repair (Amst) 3 2004 1091 1101
15. L. Tentori, and G. Graziani Pharmacological strategies to increase the antitumor activity of methylating agents Curr Med Chem 9 2002 1285 1301
16. L. Tentori, and G. Graziani Temozolomide: an update on pharmacological strategies to increase its antitumor activity Med Chem Rev Online 1 2004 144 150
17. S. Boulton, L.C. Pemberton, J.K. Porteous, N.J. Curtin, R.J. Griffin, and B.T. Golding Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors Br J Cancer 72 1995 849 856
18. S.R. Wedge, J.K. Porteous, and E.S. Newlands 3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity Br J Cancer 74 1996 1030 1036
19. L. Tentori, L. Orlando, P.M. Lacal, E. Benincasa, I. Faraoni, and E. Bonmassar Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide Mol Pharmacol 52 1997 249 258
20. L. Tentori, M. Turriziani, D. Franco, A. Serafino, L. Levati, and R. Roy Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds Leukemia 13 1999 901 909
21. L. Tentori, P.M. Lacal, E. Benincasa, D. Franco, I. Faraoni, and E. Bonmassar Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase J Pharmacol Exp Ther 285 1998 884 893
22. L. Tentori, I. Portarena, E. Bonmassar, and G. Graziani Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells Cell Death Differ 8 2001 457 469
23. L. Tentori, I. Portarena, M. Barbarino, A. Balduzzi, L. Levati, and M. Vergati Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor Mol Pharmacol 63 2003 192 202
24. L. Tentori, I. Portarena, F. Torino, M. Scerrati, P. Navarra, and G. Graziani Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells Glia 40 2002 44 54
25. N.J. Curtin, L.Z. Wang, A. Yiakouvaki, S. Kyle, C.A. Arris, and S. Canan-Koch Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells Clin Cancer Res 10 2004 881 889
26. R.J. Griffin, N.J. Curtin, D.R. Newell, B.T. Golding, B.W. Durkacz, and A.H. Calvert The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy Biochimie 77 1995 408 422
27. L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, I. Portarena, and G. Zupi Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site Blood 99 2002 2241 2244
28. L. Tentori, C. Leonetti, M. Scarsella, G. D'Amati, M. Vergati, and I. Portarena Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma Clin Cancer Res 9 2003 5370 5379
29. L. Tentori, C. Leonetti, M. Scarsella, M. Vergati, W. Xu, and D. Calvin Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors Int J Oncol 26 2005 415 422
30. C.R. Calabrese, R. Almassy, S. Barton, M.A. Batey, A.H. Calvert, and S. Canan-Koch Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361 J Natl Cancer Inst 96 2004 56 67
31. S.J. Miknyoczki, S. Jones-Bolin, S. Pritchard, K. Hunter, H. Zhao, and W. Wan Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor Mol Cancer Ther 2 2003 371 382
32. Y. Zhang, F.X. Chen, P. Mehta, and B. Gold Groove- and sequence-selective alkylation of DNA by sulfonate esters tethered to lexitropsins Biochemistry 32 1993 7954 7965
33. L. Encell, D.E. Shuker, P.G. Foiles, and B. Gold The in vitro methylation of DNA by a minor groove binding methyl sulfonate ester Chem Res Toxicol 9 1996 563 567
34. L. Tentori, P. Vernole, P.M. Lacal, R. Madaio, I. Portarena, and L. Levati Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells Leukemia 14 2000 1451 1459
35. L. Tentori, A. Balduzzi, I. Portarena, L. Levati, P. Vernole, and B. Gold Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester Cell Death Differ 8 2001 817 828
36. L. Tentori, I. Portarena, P. Vernole, B. Gold, and G. Graziani Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes Cancer Chemother Pharmacol 49 2002 217 224
37. L. Tentori, O. Forini, E. Fossile, A. Muzi, M. Vergati, and I. Portarena N3-methyladenine induces early poly (ADP-ribosylation), reduction of NF-kB DNA binding ability and nuclear up-regulation of telomerase activity Mol Pharmacol 67 2005 572 581
38. K.H. Shin, M.K. Kang, E. Dicterow, A. Kameta, M.A. Baluda, and N.H. Park Introduction of human telomerase reverse transcriptase to normal human fibroblasts enhances DNA repair capacity Clin Cancer Res 10 2004 2551 2560
39. D.R. Beidler, J.Y. Chang, B.S. Zhou, and Y.C. Cheng Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines Cancer Res 56 1996 345 353
40. C.A. Delaney, L.Z. Wang, S. Kyle, A.W. White, A.H. Calvert, and N.J. Curtin Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines Clin Cancer Res 6 2000 2860 2867
41. K.J. Bowman, D.R. Newell, A.H. Calvert, and N.J. Curtin Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro Br J Cancer 84 2001 106 112
42. C.R. Calabrese, M.A. Batey, H.D. Thomas, B.W. Durkacz, L.Z. Wang, and S. Kyle Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies Clin Cancer Res 9 2003 2711 2718
43. M. Malanga, and F.R. Althaus Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing J Biol Chem 279 2004 5244 5248
44. M.L. Kuo, S.C. Shen, C.H. Yang, S.E. Chuang, A.L. Cheng, and T.S. Huang Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity Oncogene 17 1998 2225 2234
45. S. Chatterjee, M.F. Cheng, R.B. Berger, S.J. Berger, and N.A. Berger Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide Cancer Res 55 1995 868 873
46. Y. Canitrot, G. de Murcia, and B. Salles Decreased expression of topoisomerase IIbeta in poly(ADP-ribose) polymerase-deficient cells Nucleic Acids Res 26 1998 5134 5138
47. S. Kubo, M. Matsutani, K. Nakagawa, T. Ogura, H. Esumi, and N. Saijo Participation of poly(ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines J Cancer Res Clin Oncol 118 1992 244 248
48. J. Wesierska-Gadek, D. Schloffer, M. Gueorguieva, M. Uhl, and A. Skladanowski Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest Cancer Res 64 2004 4487 4497
49. J.A. Munoz Gamez, D. Martin-Oliva, R. Aguilar-Queseda, A. Canuelo, M.I. Nunez, and T. Valenzuela PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis Biochem J 386 2005 119 125
50. G. Wurzer, Z. Herceg, and J. Wesierska-Gadek Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein Cancer Res 60 2000 4238 4244
51. G. Chen, and W.J. Zeller Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo Cancer Chemother Pharmacol 33 1993 157 162
52. P. Pacher, L. Liaudet, P. Bai, L. Virag, J.G. Mabley, and G. Hasko Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure J Pharmacol Exp Ther 300 2002 862 867
53. I. Racz, K. Tory, F. Gallyas Jr., Z. Berente, E. Osz, and L. Jaszlits BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity Biochem Pharmacol 63 2002 1099 1111
54. Y. Shino, Y. Itoh, T. Kubota, T. Yano, T. Sendo, and R. Oishi Role of poly(ADP-ribose)polymerase in cisplatin-induced injury in LLC-PK1 cells Free Radic Biol Med 35 2003 966 977
55. G. Bardos, K. Moricz, L. Jaszlits, G. Rabloczky, K. Tory, and I. Racz BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats Toxicol Appl Pharmacol 190 2003 9 16
56. S.S. Agarwala, J.M. Kirkwood, M. Gore, B. Dreno, N. Thatcher, and B. Czarnetski Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study J Clin Oncol 22 2004 2101 2107